In 2021, SARS-CoV-2 mRNA Vaccine entered Phase Ⅲ clinical trial, and Recombinant SARS-CoV-2 Vaccine (Chimpanzee Adenoviral Vector) which is co-developed with Tsinghua University and Tianjin Medical University entered Phase Ⅰ clinical trial. Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Pichia pastoris) is expected to launch in the near future.